These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 29504427)

  • 1. A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01).
    Palaparthy R; Udata C; Hua SY; Yin D; Cai CH; Salts S; Rehman MI; McClellan J; Meng X
    Expert Rev Clin Immunol; 2018 Apr; 14(4):329-336. PubMed ID: 29504427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
    Cohen SB; Alten R; Kameda H; Hala T; Radominski SC; Rehman MI; Palaparthy R; Schumacher K; Schmitt S; Hua SY; Ianos C; Sewell KL
    Arthritis Res Ther; 2018 Jul; 20(1):155. PubMed ID: 30053896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects.
    Shin D; Kim Y; Kim YS; Körnicke T; Fuhr R
    BioDrugs; 2015 Dec; 29(6):381-8. PubMed ID: 26577771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis.
    Palaparthy R; Rehman MI; von Richter O; Yin D
    Expert Opin Biol Ther; 2019 Oct; 19(10):1065-1074. PubMed ID: 31284794
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single-Blind, Single-Dose, Parallel-Group Study in Healthy Subjects.
    Chow V; Oh M; Gessner MA; Fanjiang G
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):246-255. PubMed ID: 31628783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial.
    Cohen SB; Radominski SC; Kameda H; Kivitz AJ; Tee M; Cronenberger C; Zhang M; Hackley S; Rehman MI; von Richter O; Alten R
    BioDrugs; 2020 Apr; 34(2):197-207. PubMed ID: 31939063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study.
    Park W; Lee SJ; Yun J; Yoo DH
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S25-31. PubMed ID: 26395834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis.
    Cohen S; Emery P; Greenwald M; Yin D; Becker JC; Melia LA; Li R; Gumbiner B; Thomas D; Spencer-Green G; Meng X
    Br J Clin Pharmacol; 2016 Jul; 82(1):129-38. PubMed ID: 26909489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54.
    Alten R; Batko B; Hala T; Kameda H; Radominski SC; Tseluyko V; Babic G; Cronenberger C; Hackley S; Rehman M; von Richter O; Zhang M; Cohen S
    RMD Open; 2019; 5(1):e000876. PubMed ID: 30997153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers.
    Knight B; Rassam D; Liao S; Ewesuedo R
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):839-46. PubMed ID: 26984210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects.
    Zhang T; Chen G; Liu C; Zu L; Wang Q; Wang Y; Lv J; An Y; Dong L; Cheng H; Ren S; Wang Q; Zheng Q; Song H; Fang Y
    BioDrugs; 2019 Feb; 33(1):93-100. PubMed ID: 30511316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers.
    Shin D; Lee YJ; Choi J; Lee D; Park M; Petkova M
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):567-575. PubMed ID: 32949267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males.
    Cho SH; Han S; Ghim JL; Nam MS; Yu S; Park T; Kim S; Bae J; Shin JG
    BioDrugs; 2019 Apr; 33(2):173-181. PubMed ID: 30850957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men.
    Markus R; Chow V; Pan Z; Hanes V
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):755-763. PubMed ID: 28864922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects.
    Lee YJ; Shin D; Kim Y; Kang J; Gauliard A; Fuhr R
    Br J Clin Pharmacol; 2016 Jul; 82(1):64-73. PubMed ID: 26972584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis.
    Kameda H; Uechi E; Atsumi T; Abud-Mendoza C; Kamei K; Matsumoto T; Ponce de Leon D; Rehman MI; Zhang M; Radominski SC
    Int J Rheum Dis; 2020 Jul; 23(7):876-881. PubMed ID: 32476277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
    Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.
    Hyland E; Mant T; Vlachos P; Attkins N; Ullmann M; Roy S; Wagner V
    Br J Clin Pharmacol; 2016 Oct; 82(4):983-93. PubMed ID: 27285856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
    Chen X; Li C; Ewesuedo R; Yin D
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta
    Moosavi S; Borema T; Ewesuedo R; Harris S; Levy J; May TB; Summers M; Thomas JS; Zhang J; Yao HM
    Adv Ther; 2020 Jul; 37(7):3370-3391. PubMed ID: 32524499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.